Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 4/20 | 0.52 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.46 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 4/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1892037 | 1.00 | PTGER3 (0.52) | PTGER3PTGDRALDH1A1KDM4EPKM | |
| SCHEMBL12660704 | 0.89 | MEN1 (0.45) | PTGER3PTGDRALDH1A1KDM4EPKM | |
| SCHEMBL15402847 | 0.83 | THRB (0.46) | PTGER3ALDH1A1PTGER4PTGER2 | |
| SCHEMBL15402845 | 0.83 | THRB (0.46) | PTGER3ALDH1A1PTGER4PTGER2 | |
| SCHEMBL12419819 | 0.81 | ALOX5 (0.41) | HDAC8MAOB | |
| SCHEMBL6069398 | 0.80 | MAOB (0.57) | ALDH1A1DGAT1MAOB | |
| SCHEMBL20607798 | 0.78 | DGAT1 (0.48) | PKMDGAT1MAOB | |
| SCHEMBL21772156 | 0.78 | DGAT1 (0.50) | PKMDGAT1MAOB | |
| SCHEMBL29876160 | 0.78 | DGAT1 (0.50) | PKMDGAT1MAOB | |
| SCHEMBL20805182 | 0.78 | DGAT1 (0.52) | DGAT1MAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | UNIVERSITAT DE VALÈNCIA (ES) | 2020-01-28 | — | — | US | disclosed |
| US-20180179139-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2018-06-28 | — | — | US | disclosed |
| US-20160083327-A1 | GPBP inhibition using Q2 peptidomimetics | JUAN SAUS (ES) | 2016-03-24 | — | — | US | disclosed |
| US-9199936-B2 | GPBP inhibition using Q2 peptidomimetics | Fibrostatin Sociedad Limitada (ES) | 2015-12-01 | — | — | US | disclosed |
| EP-2496544-B1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | FIBROSTATIN S L (SE) | 2014-08-20 | — | — | EP | disclosed |
| US-20140080852-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2014-03-20 | — | — | US | disclosed |
| US-8586776-B2 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2013-11-19 | — | — | US | disclosed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | PTGER3 1841/4885PTGDR 1968/4885ALDH1A1 3689/4885 |
| US-20140080852-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | PTGER3 1841/4885PTGDR 1968/4885ALDH1A1 3689/4885 |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | PTGER3 1841/4885PTGDR 1968/4885ALDH1A1 3689/4885 |
| US-20180179139-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | PTGER3 1841/4885PTGDR 1968/4885ALDH1A1 3689/4885 |
| US-20160083327-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | PTGER3 1841/4885PTGDR 1968/4885ALDH1A1 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.